Virbac SA
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. The company offers a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. I… Read more
Market Cap & Net Worth: Virbac SA (VRBCF)
Virbac SA (PINK:VRBCF) has a market capitalization of $2.71 Billion ($2.71 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #6225 globally and #3524 in its home market, demonstrating a -0.17% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Virbac SA's stock price $324.00 by its total outstanding shares 8377824 (8.38 Million).
Virbac SA Market Cap History: 2015 to 2025
Virbac SA's market capitalization history from 2015 to 2025. Data shows growth from $1.95 Billion to $2.71 Billion (5.03% CAGR).
Virbac SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Virbac SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.29x
Virbac SA's market cap is 2.29 times its annual revenue
0.84x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
22.03x
Virbac SA's market cap is 22.03 times its annual earnings
11.15x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.95 Billion | $852.62 Million | $9.40 Million | 2.28x | 206.85x |
| 2016 | $1.44 Billion | $871.83 Million | $34.65 Million | 1.65x | 41.64x |
| 2017 | $1.20 Billion | $861.88 Million | -$2.58 Million | 1.39x | N/A |
| 2018 | $1.24 Billion | $868.93 Million | $20.10 Million | 1.43x | 61.83x |
| 2019 | $1.93 Billion | $938.34 Million | $51.55 Million | 2.06x | 37.50x |
| 2020 | $2.23 Billion | $934.20 Million | $136.04 Million | 2.39x | 16.42x |
| 2021 | $3.60 Billion | $1.06 Billion | $113.16 Million | 3.38x | 31.79x |
| 2022 | $3.32 Billion | $1.22 Billion | $121.97 Million | 2.73x | 27.18x |
| 2023 | $2.39 Billion | $1.25 Billion | $121.30 Million | 1.92x | 19.74x |
| 2024 | $3.20 Billion | $1.40 Billion | $145.29 Million | 2.29x | 22.03x |
Competitor Companies of VRBCF by Market Capitalization
Companies near Virbac SA in the global market cap rankings as of March 18, 2026.
Key companies related to Virbac SA by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
Virbac SA Historical Marketcap From 2015 to 2025
Between 2015 and today, Virbac SA's market cap moved from $1.95 Billion to $ 2.71 Billion, with a yearly change of 5.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $2.71 Billion | -15.18% |
| 2024 | $3.20 Billion | +33.63% |
| 2023 | $2.39 Billion | -27.76% |
| 2022 | $3.32 Billion | -7.85% |
| 2021 | $3.60 Billion | +61.05% |
| 2020 | $2.23 Billion | +15.57% |
| 2019 | $1.93 Billion | +55.56% |
| 2018 | $1.24 Billion | +3.98% |
| 2017 | $1.20 Billion | -17.15% |
| 2016 | $1.44 Billion | -25.85% |
| 2015 | $1.95 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Virbac SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.71 Billion USD |
| MoneyControl | $2.71 Billion USD |
| MarketWatch | $2.71 Billion USD |
| marketcap.company | $2.71 Billion USD |
| Reuters | $2.71 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.